Men's Health

These are Urology Times' most-read prostate cancer articles of 2016.

Researchers at UCLA have discovered a previously unrecognized type of progenitor cell in inflamed areas of the prostate that have the ability to initiate cancer in response to genetic changes.

Other products discussed include a stent system for treating ureteral obstructions, a male infertility test, and more.

These four videos depict expert techniques for buried penis repair.

Fewer than 20% of patients with biochemical recurrence after radical prostatectomy develop metastasis, and a smaller proportion die as a result of prostate cancer.

Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.

"There are significant data examining the role of heat exposure to male sperm. However, none of it is very high quality and the data are murky at best," write James R. Craig, MD, MS; William Brant, MD; and James M. Hotaling, MD, MS.

A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.

Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.

Although a recent study of testosterone therapy does not fulfill the need for large-scale, randomized, controlled studies of the treatment, “it is very informative in several ways,” writes Arthur L. Burnett, II, MD, MBA.

Long-term testosterone therapy in hypogonadal men improves urinary function and erectile function compared with untreated controls, according to registry data from a single practice.

“I think we’re seeing more younger men coming in with erectile dysfunction, because there’s just a lot more publicity about the issue," one urologist said.

Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.

The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.

In this interview, Daniel Shoskes, MD, discusses his evaluation of patients with scrotal pain, outlines his use of conservative treatments, and explains surgical approaches and how he decides whether to use them.

Urologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.

A new study revealing 91% of very low-risk and 74% of low-risk prostate cancer patients in Sweden choose active surveillance should be a benchmark for the use of the management strategy in the U.S. and elsewhere in the world, the study’s authors say.

Hypogonadism in men undergoing artificial urinary sphincter (AUS) implantation significantly increases the risk of cuff erosion, according to the results of a study presented by urologists from UT Southwestern Medical Center, Dallas.

Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.

In this video, M. Chad Wallis, MD, demonstrates the Cohen cross-trigonal ureteral reimplant, considered the most commonly performed open reimplant procedure.

In this video, Chester J. Koh, MD, shows key steps in a top-down approach without the use of stents for robot-assisted extravesical ureteral reimplantation.

Another study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.

New research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.

Recent data show that a low-carbohydrate diet may have significant positive effects in men on hormonal therapy for prostate cancer, including metabolic effects. In this interview, study author Stephen J. Freedland, MD, discusses his group’s findings, ongoing research on diet and lifestyle changes in men with prostate cancer, and how he counsels patients.